Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Long Non-Coding Rna (Lncrna) Dscam-As1 Is Upregulated in Breast Cancer Publisher Pubmed



Tarighi M1 ; Khalajkondori M2 ; Hosseinzadeh A3 ; Abtin M4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biology, Tabriz Branch, Islamic Azad University, Tabriz, Iran
  2. 2. Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
  3. 3. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
  4. 4. Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Breast Disease Published:2021


Abstract

BACKGROUND: Accumulating evidence highlights that long noncoding RNA (lncRNA) DSCAM-AS1 play a key regulatory role in different stages of cancer development and progression. This study aimed to investigate whether the expression of DSCAM-AS1 is deregulated in breast cancer. MATERIALS AND METHODS: The relative expression of DSCAM-AS1 was measured in fifty breast cancerous and matched adjacent non-neoplastic tissue samples using quantitative real-time polymerase chain reaction (qPCR) technique. The association between DSCAM-AS1 expression and patients' clinicopathological features was evaluated. Sensitivity and specificity of the DSCAM-AS1 expression for diagnosing breast cancer was obtained by the receiver operating characteristic (ROC) curve analysis. RESULTS: Our results showed that the expression of DSCAM-AS1 was significantly up-regulated in breast cancerous tissues compared with the matched adjacent non-neoplastic tissues (P < 0.05). Furthermore, we observed a significant association between the DSCAM-AS1 expression and lymph node metastasis (P = 0.011) but no other clinicopathological characteristics (P > 0.05). ROC curve analysis resulted in an area under the curve (AUC) of 0.67 and showed that the DSCAM-AS1 expression level may discriminate cancerous and non-cancerous tissues with 68% sensitivity and 76% specificity. CONCLUSION: This study provides further evidence that the expression of DSCAM-AS1 is deregulated in breast cancer and highlights its potential in breast cancer development. © 2021 - IOS Press. All rights reserved.